Company Overview and News

 
To sell or not to sell?

2018-09-29 thestar.com.my
Late Friday last week, little known Pinehill Pacific Bhd (formerly known as Multi Vest Resources Bhd, which by the way was formerly known as Best World Land Bhd) surprised the market with the announcement that it was parting with nearly 9,000 acres of landbank and related plantation assets held via three subsidiary companies to United Plantations Bhd (UP) for a whopping sum of RM413.6mil.
2038 5138 1996 UPBMF 4383 7501 1902 2089 5112

 
TH Plantation’s 2Q net profit tumbles 99% on lower selling prices

2018-08-29 theedgemarkets
KUALA LUMPUR (Aug 29): TH Plantations Bhd’s second quarter net profit plummeted by a massive 99% to RM200,000 from RM25.76 million a year ago, which the group blames on lower crude palm oil (CPO) and palm kernel prices.
5112

 
Danajamin welcomes newly-appointed chairman and directors

2018-08-28 theedgemarkets
KUALA LUMPUR (Aug 28): Danajamin Nasional Bhd has appointed Md. Yusof Hussin as the new chairman of its board, effective Aug 23, 2018.
1155 4588 MLYBY 1368 MLYNF 5112

 
TH Plantations CEO quits after a week on garden leave

2018-08-20 theedgemarkets
KUALA LUMPUR (Aug 20): TH Plantations Bhd's chief executive officer (CEO) and executive director (ED) Datuk Seri Zainal Azwar Zainal Aminuddin has resigned from the group one week after being asked to go on garden leave.
1023 5258 BSMAF 5112 1818 CIMDF

 
TH Plantations CEO on garden leave; tasks assumed by CFO

2018-08-15 theedgemarkets
KUALA LUMPUR: TH Plantations Bhd said its chief executive officer (CEO) cum executive director Datuk Seri Zainal Azwar Zainal Aminuddin had been given garden leave from yesterday until further notice.
5112

 
TH Plantations CEO on garden leave

2018-08-15 thestar.com.my
In Zainal’s(pic) absence, Mohamed Azman Shah Ishak, the company’s chief financial officer, will assume the day-to-day management of the group and its subsidiaries.
BSMAF 5112 1818

 
TH Plantations puts CEO Zainal Azwar on garden leave

2018-08-14 malaymail
KUALA LUMPUR, Aug 14 — TH Plantations Bhd (THP) today announced that its Chief Executive Officer/Executive Director, Datuk Seri Zainal Azwar Zainal Aminuddin, has been given garden leave commencing from Aug 14, 2018 until further notice.
BSMAF 5112 1818

 
TH Plantations CEO on garden leave, tasks assumed by CFO

2018-08-14 theedgemarkets
KUALA LUMPUR (Aug 14): TH Plantations Bhd said its chief executive officer cum executive director Datuk Sri Zainal Azwar Zainal Aminuddin has been given garden leave from today until further notice.
5112

 
TH Plantations puts CEO on garden leave

2018-08-14 thestar.com.my
TH Plantations CEO Datuk Seri Zainal Azwar Zainal Aminuddin (left) and CFO Mohamed Azman Shah Ishak at the company's AGM last year.
BSMAF 5112 1818

 
Tabung Haji CEO Zukri Samat is TH Plantations chairman

2018-08-14 theedgemarkets
KUALA LUMPUR: Lembaga Tabung Haji’s newly appointed group managing director (MD) and chief executive officer (CEO) Datuk Seri Zukri Samat is taking on the role of non-independent and non-executive chairman of TH Plantations Bhd as well.
5258 5112

2
KLCI to track global loss, support seen at 1,770

2018-08-13 theedgemarkets
KUALA LUMPUR (Aug 14): The FBM KLCI is seen extending its loss today, tracking the overnight weaker close at most global markets, with support at the 1,770-point level.
5087 5102 5112 MSCI

 
Guan Chong, Mycron, Mynews, Malton, Pavilion REIT, TH Plantations and Vivocom

2018-08-13 theedgemarkets
KUALA LUMPUR (Aug 13): Based on corporate announcements and news flow today, stocks in focus tomorrow may include the following: Guan Chong Bhd, Mycron Steel Bhd, Mynews Holdings Bhd, Malton Bhd, Pavilion REIT, TH Plantations Bhd and Vivocom.
3778 5087 5102 5112

 
Tabung Haji CEO Zukri Samat is chairman of TH Plantations

2018-08-13 theedgemarkets
KUALA LUMPUR (Aug 13): Lembaga Tabung Haji’s newly appointed group managing director and chief executive officer (CEO) Datuk Seri Zukri Samat is taking on the role of non-independent and non-executive chairman of TH Plantations Bhd as well.
5258 5112

 
Maybank IB sees lower earnings for plantation sector

2018-08-07 thestar.com.my
PETALING JAYA: Lower earnings are expected for the plantation sector in the upcoming second quarter (Q2’18) results season, says Maybank Investment Bank (IB) Research.
5126 SARKF 9059 5112 5254

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...